Natural cannabinoids only have a limited affinity for the endocannabinoid synapse.
>Studies have found that these compounds tend to activate the CB1 receptor to a greater degree than does THC, suggesting that synthetic marijuana compounds have the ability to induce far more intense effects than marijuana, according to the review.
https://www.livescience.com/57747-synthetic-marijuana-risks....
>Much of our understanding of cannabinoid tolerance, dependence and withdrawal has been based on studies involving Δ9-THC, a relatively weak partial agonist at CB1 and CB2 receptors. However, the SCBs commonly found in quasi-legal commercial products such as K2 and Spice are typically full cannabinoid receptor agonists. Importantly, a drug's efficacy determines how “powerful” its maximal effects may be in biological systems. A low efficacy cannabinoid like Δ9-THC will have a less pronounced maximal effect than a higher efficacy cannabinoid, such as the SCBs present in commercial products, and this difference in maximal effects cannot be overcome simply by increasing the dose of Δ9-THC. In other words, no amount of Δ9-THC can stimulate cannabinoid receptors to the same degree as the SCBs currently emerging as drugs of abuse. This has left researchers working with these high efficacy SCBs in the unusual position of having to determine whether their effects are related to the unprecedented degree of cannabinoid receptor stimulation elicited by these compounds, or whether they are produced by interactions with other, non-cannabinoid receptor systems.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4582439/